Thompson Rivers University's dean of trades says he expects a large injection of provincial dollars will at least double ...
Bioventus stock is upgraded to a "Buy" amid a breakout driven by favorable regulatory developments. Here's what investors ...
I am a physician with good insurance, but every year we have faced higher out-of-pocket cost for my son’s EpiPen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results